Kamada (KMDA) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kamada (KMDA) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 18.6% versus a loss of 57.8%. Over five years, KMDA leads with a +49.7% price change compared with -55.8% for SPRY. ARS Pharmaceuticals is the larger company by market cap ($453.5 million vs $448.7 million), about 1.0 times the size.
Kamada pays a dividend yielding 3.22%, while ARS Pharmaceuticals does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KMDA | SPRY |
|---|---|---|
| Share price | $7.78 | $4.56 |
| Market cap | $448.70M | $453.48M |
| 1-day change | -1.46% | +4.59% |
| YTD return | +11.76% | -62.58% |
| 1-year return | +18.65% | -57.79% |
| 5-year return | +49.72% | -55.78% |
| P/E ratio (TTM) | 20.46 | — |
| Forward P/E | 13.48 | — |
| EPS (TTM) | $0.38 | $-2.18 |
| Dividend yield | 3.22% | 0.00% |
| Annual dividend | $0.25 | $0.00 |
| 52-week high | $9.35 | $13.15 |
| 52-week low | $6.55 | $3.99 |
| Distance from 52-week high | -16.84% | -65.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +73.63% | +393.42% |
| Average volume | 118.04K | 1.85M |
| Shares outstanding | 57.71M | 99.45M |
| Employees | 462 | 195 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed SPRY by 76.4 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (3.22% vs 0.00%).
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 195 employees
KMDA vs SPRY FAQ
Which is bigger, Kamada or ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $453.48M compared with $448.70M for Kamada (KMDA).
Which stock has performed better over the past year, KMDA or SPRY?
KMDA returned +18.65% over the past 12 months, compared with -57.79% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Kamada or ARS Pharmaceuticals?
Kamada pays a dividend yielding 3.22%, while ARS Pharmaceuticals does not currently pay a regular dividend.
Are Kamada and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.